Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A. Girish S, et al. Among authors: vogel cl. Cancer Chemother Pharmacol. 2012 May;69(5):1229-40. doi: 10.1007/s00280-011-1817-3. Epub 2012 Jan 20. Cancer Chemother Pharmacol. 2012. PMID: 22271209 Free PMC article. Clinical Trial.
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. Burris HA 3rd, et al. Among authors: vogel cl. J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20. J Clin Oncol. 2011. PMID: 21172893 Clinical Trial.
Efficacy of trastuzumab.
Vogel CL, Reddy JC, Reyno LM. Vogel CL, et al. Cancer Res. 2005 Mar 1;65(5):2044. doi: 10.1158/0008-5472.CAN-04-3943. Cancer Res. 2005. PMID: 15753405 No abstract available.
Dual HER2-targeted approaches in HER2-positive breast cancer.
Ahn ER, Vogel CL. Ahn ER, et al. Among authors: vogel cl. Breast Cancer Res Treat. 2012 Jan;131(2):371-83. doi: 10.1007/s10549-011-1781-y. Epub 2011 Sep 29. Breast Cancer Res Treat. 2012. PMID: 21956210 Review.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
195 results